How did foreign currency fluctuations impact Abbott's reported sales?

The strengthening U.S. dollar had a significant negative impact on reported sales. In the second quarter of 2015, foreign exchange unfavorably impacted total international sales by 12.4% and total net sales by 8.6%. For the first six months of 2015, the impact was a 7.8% reduction in international sales and a 7.8% reduction in total net sales.

What were the key growth drivers for Abbott in this period?

The primary growth drivers were the strategic acquisitions of CFR Pharmaceuticals and Veropharm, which significantly expanded Abbott's presence in emerging markets. Sales in 'Key Emerging Markets' for the Established Pharmaceutical Products segment, excluding foreign exchange, surged by 43.9% for the six months. Double-digit growth was also observed in International Pediatric Nutritional sales and International Adult Nutritional sales (excluding foreign exchange).

What is the status of the Medical Optics reporting unit's goodwill?

The Medical Optics reporting unit has approximately $2 billion in goodwill. While its fair value currently exceeds its carrying value by approximately 15%, Abbott is monitoring potential risks such as lower-than-projected growth rates, regulatory delays, negative foreign currency movements, and increased discount rates, which could lead to future impairment testing.

How did the company's profitability metrics change?

Gross profit margin showed a notable improvement, increasing from 52.1% in Q2 2014 to 54.2% in Q2 2015, and from 50.9% for the first six months of 2014 to 54.2% for the same period in 2015. This improvement is attributed to gross margin initiatives and, in part, foreign exchange impacts within the Diagnostics and Nutritional businesses.

ABT 10-Q Quarterly Report Q2 FY2015 — Revenue, Net Income, EPS

Summary

Abbott Laboratories reported solid financial results for the second quarter and first six months of 2015, demonstrating resilience despite a challenging foreign exchange environment. Total net sales grew by 2.2% to $5.17 billion for the quarter and 2.6% to $10.07 billion for the six months, with a significant portion of this growth (10.8% excluding foreign exchange) driven by strategic acquisitions completed in 2014 and strong performance in emerging markets. The company's gross profit margin also saw improvement, rising to 54.2% in both the quarter and year-to-date period, indicating effective cost management and operational efficiencies. Key growth drivers included the Established Pharmaceutical Products segment, particularly in emerging markets, and double-digit growth in International Pediatric Nutritionals. While some segments like Diagnostic Products and Vascular Products experienced slight declines or modest growth, the overall performance was bolstered by the integration of CFR Pharmaceuticals and Veropharm. The company continues to manage its capital effectively, returning value to shareholders through dividends and share repurchases, while also investing in research and development to fuel future growth.

Financial Highlights

55 data points

Beta

Revenue

$5.17B

0.5% Gross Margin

Net Income

$784.00M

0.2% Net Margin

EPS (Diluted)

$0.52

Total Assets

$44.13B

Cash & Equivalents

$4.05B

Free Cash Flow

$725.00M

Financial Statements

Beta

Revenue	$5.17B
Cost of Revenue	$2.22B
Gross Profit	$2.80B
SG&A Expenses	$1.73B
Operating Expenses	$4.44B
Operating Income	$729.00M
Interest Expense	$44.00M
Net Income	$784.00M
EPS (Basic)	$0.52
EPS (Diluted)	$0.52
Shares Outstanding (Basic)	1.49B
Shares Outstanding (Diluted)	1.50B

Key Highlights

1Total net sales increased by 2.2% to $5.17 billion in Q2 2015 and 2.6% to $10.07 billion for the first six months of 2015.
2Excluding the impact of foreign exchange, total net sales increased by 10.8% in Q2 2015 and 10.4% for the first six months, boosted by acquisitions and emerging market growth.
3Established Pharmaceutical Products showed robust growth, with sales up 31.3% in Q2 and 31.5% year-to-date, largely driven by a 43.9% increase in Key Emerging Markets (excluding FX).
4Gross profit margin improved to 54.2% for Q2 2015 and year-to-date, up from 52.1% and 50.9% respectively in the prior year, reflecting margin initiatives.
5The company successfully integrated recent acquisitions, CFR Pharmaceuticals and Veropharm, contributing to sales growth, especially in emerging markets.
6International Pediatric Nutritional sales grew 2.3% (8.4% ex-FX) for the six months, with double-digit growth in China and Latin America.
7Abbott continues to return capital to shareholders, with share repurchases and dividends funded by operating cash flow and existing cash reserves.

ABBOTT LABORATORIES Quarterly Report for Q2 Ended Jun 30, 2015

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions